BioIntelliSense develops a medical-grade continuous health monitoring platform for Remote Patient Monitoring (RPM), spanning care settings from hospital wards to the home. Its flagship product, the BioButton, is an FDA-cleared wearable device that captures multi-parameter vital signs, physiological biometrics, and symptomatic events on a continuous basis. Data flows through a suite of integrated components - BioHub (device connectivity gateways), BioMobile (patient and clinician mobile applications), BioCloud (cloud data storage and management), and BioDashboard (a clinical intelligence interface) - forming an end-to-end Data-as-a-Service (DaaS) platform.
The clinical use case centres on early detection of patient deterioration. According to the company, continuous monitoring through its platform can identify declining patients hours earlier than traditional intermittent monitoring. Clinical evidence cited by BioIntelliSense associates the platform with reductions in unplanned ICU admissions, rapid response team activations, and average hospital length of stay. The BioDashboard provides clinicians with high-resolution vital sign trending and data-driven insights to support clinical decision-making.
The technical domains involved in building and operating the platform span wearable medical device engineering, cloud data services, mobile health applications, device connectivity, and clinical intelligence systems. The company operates within the United States, as indicated by its FDA regulatory status.
